Kymera Therapeutics (KYMR) Share-based Compensation (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Share-based Compensation data on file, last reported at $16.0 million in Q1 2026.

• On a quarterly basis, Share-based Compensation rose 12.46% year-over-year to $16.0 million in Q1 2026; TTM through Mar 2026 was $205000.0, a 90.95% decrease from a year earlier, with the FY2025 full-year figure at $63.4 million, down 7.31% from the prior year.
• Share-based Compensation for Q1 2026 stood at $16.0 million, up from -$45.5 million in the prior quarter.
• Over the last five years, Share-based Compensation for KYMR reached as high as $73.5 million in Q3 2025 and fell as low as -$45.5 million in Q4 2025.
• Historically, Share-based Compensation has averaged $9.0 million across 5 years, with a median of $11.4 million in 2023.
• Across the five-year window, Share-based Compensation tumbled 478.17% in 2024 and soared 393.16% in 2025, its largest moves.
• Year by year, Share-based Compensation stood at $9.1 million in 2022, then climbed by 20.07% to $10.9 million in 2023, then tumbled by 478.17% to -$41.2 million in 2024, then decreased by 10.28% to -$45.5 million in 2025, then jumped by 135.22% to $16.0 million in 2026.
• Per Business Quant data, the three most recent Share-based Compensation figures were $16.0 million in Q1 2026, -$45.5 million in Q4 2025, and $73.5 million in Q3 2025.